| Identification | Back Directory | [Name]
4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRIMIDINE | [CAS]
126352-69-0 | [Synonyms]
5-a]pyriMidine
7-tetrahydropyrazolo[1
4H,5H,6H,7H-pyrazolo[1,5-a]pyrimidine
4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRIMIDINE
1,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine
Pyrazolo[1,5-a]pyriMidine,4,5,6,7-tetrahydro-
4,5,6,7-Tetrahydropyrazolo[1,5-a]pyriMidine 2HCl
4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine(HCl salt)
4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine hydrochloride | [Molecular Formula]
C6H9N3 | [MDL Number]
MFCD08273904 | [MOL File]
126352-69-0.mol | [Molecular Weight]
123.16 |
| Chemical Properties | Back Directory | [Boiling point ]
290℃ | [density ]
1.33 | [Fp ]
129℃ | [storage temp. ]
Keep in dark place,Inert atmosphere,Room temperature | [pka]
4.52±0.20(Predicted) | [Appearance]
Off-white to yellow Solid |
| Hazard Information | Back Directory | [Uses]
4,5,6,7-Tetrahydropyrazolo[1,5-a]pyrimidine can be used as FGFR inhibitors to treat FGFR3-associated diseases, such as, cancer. | [Synthesis]
To a solution of 3H-pyrazol-3-amine (9.8 g, 0.1 mol) and triethylamine (TEA, 36.0 g, 0.3 mol) in 1,4-dioxane (200 mL) was added 1,3-dibromopropane (26.3 g, 0.1 mol). The reaction mixture was stirred at 110 °C for 5 hours. After the reaction was complete, the mixture was filtered. The filtrate was concentrated to dryness. The residue was purified by silica gel column chromatography (eluent: dichloromethane/methanol = 100/1) to afford 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine (5.3 g, yield: 36%) as a white solid.1H NMR (300 MHz, CDCl3): δ = 7.18 (s, 1H), 5.26 (s, 1H), 4.22-4.00 (m, 3H), 3.26-3.22 (m, 2H), 2.11-2.03 (m, 2H). | [References]
[1] Patent: WO2018/136890, 2018, A1. Location in patent: Paragraph 001018; 001019; 001020
[2] Bioorganic and Medicinal Chemistry, 1997, vol. 5, # 3, p. 557 - 567 |
|
| Company Name: |
Shangchem Co., Ltd.
|
| Tel: |
+86-21-68182121 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList14031/0_EN.htm |
|